CYP1A2 activity is an important determinant of clozapine dosage in schizophrenic patients

Author： Doude van Troostwijk L.J.A.E. Koopmans R.P. Vermeulen H.D.B. Guchelaar H.-J.

Publisher： Elsevier

ISSN： 0928-0987

Source： European Journal of Pharmaceutical Sciences, Vol.20, Iss.4, 2003-12, pp. : 451-457

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Smoking impact on CYP1A2 activity in a group of patients with schizophrenia

By Bozikas V.P. Papakosta M. Niopas I. Karavatos A. Mirtsou-Fidani V.

European Neuropsychopharmacology, Vol. 14, Iss. 1, 2004-01 ,pp. : 39-44

Elsevier

Access to resources Recommend Favorite

Clinical efficacy of clozapine in treatment-refractory schizophrenic patients

By Min-Soo L. In-Kwa J. Dong-Il K.

European Neuropsychopharmacology, Vol. 5, Iss. 3, 1995-09 ,pp. : 342-342

Elsevier

Access to resources Recommend Favorite

EEG abnormalities in clozapine-treated schizophrenic patients

By Treves I.A. Neufeld M.Y.

European Neuropsychopharmacology, Vol. 6, Iss. 2, 1996-05 ,pp. : 93-94

Elsevier

Access to resources Recommend Favorite

Effects of clozapine on plasma monoamine metabolites in treatment-refractory schizophrenic patients

By Min-Soo L. Seung-Hyun K.

European Neuropsychopharmacology, Vol. 5, Iss. 3, 1995-09 ,pp. : 341-342

Elsevier

Access to resources Recommend Favorite

Steady-state Pharmacokinetics of Clozapine in Refractory Schizophrenic Saudi Arabian Patients

By Hussein R. Gad A. Raines D.A. Chaleby K. Al-Rawithi S. El-Yazigi A.

Pharmacy and Pharmacology Communications, Vol. 5, Iss. 7, 1999-07 ,pp. : 473-478

Pharmaceutical Press

Access to resources Recommend Favorite